These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32866411)

  • 21. Management of advanced non-small-cell lung cancer in elderly populations.
    Lilenbaum R
    Clin Lung Cancer; 2003 Nov; 5(3):169-73. PubMed ID: 14667272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-agent vinorelbine in the treatment of non-small cell lung cancer.
    Wozniak AJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):62-6; discussion 71-2. PubMed ID: 10585010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
    Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung cancer in the elderly: current and future chemotherapeutic options.
    Hinton S; Sandler A
    Drugs Aging; 2002; 19(5):365-75. PubMed ID: 12093323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy of advanced NSCLC in special patient population.
    Gridelli C; Maione P; Rossi A; Guerriero C; Ferrara C; Del Gaizo F; Colantuoni G; Nicolella D; Napolitano L
    Ann Oncol; 2006 May; 17 Suppl 5():v72-8. PubMed ID: 16807469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
    Evans WK; Le Chevalier T
    Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
    J Natl Cancer Inst; 1999 Jan; 91(1):66-72. PubMed ID: 9890172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: a phase II study.
    Buccheri G; Ferrigno D
    Cancer; 2000 Jun; 88(12):2677-85. PubMed ID: 10870049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival.
    Lilenbaum RC; Langenberg P; Dickersin K
    Cancer; 1998 Jan; 82(1):116-26. PubMed ID: 9428487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced non-small-cell lung cancer in the elderly.
    Vamvakas L; Saloustros E; Karampeazis A; Georgoulias V
    Clin Lung Cancer; 2009 May; 10(3):158-67. PubMed ID: 19443335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel: a review of its use in non-small cell lung cancer.
    Comer AM; Goa KL
    Drugs Aging; 2000 Jul; 17(1):53-80. PubMed ID: 10933515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
    Kubota K
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
    Miller VA; Kris MG
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients.
    Veronesi A; Crivellari D; Magri MD; Cartei G; Mansutti M; Foladore S; Monfardini S
    Eur J Cancer; 1996 Sep; 32A(10):1809-11. PubMed ID: 8983294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.